Involving patients in research: the RADAR-AD Patient Advisory Board.

The first steps to create the RADAR-AD Patient Advisory Board (PAB) were taken during the meeting of Alzheimer Europe’s European Working Group of People With Dementia (EWGPWD) on 19-20 March in Luxembourg.

The members of the EWGPWD and their supporters were invited to provide input on the new IMI project RADAR AD. Interested members and supporters will have the opportunity to join the RADAR-AD Patient Advisory Board (PAB). The group provided feedback on the definition and prioritisation of functional domains in Alzheimer’s disease and main features to consider when selecting a device to measure functioning of people with dementia. They also reviewed and provided advice on the protocol for the RADAR AD clinical trial. Five members of the RADAR-AD consortium - Irene Kanter-Schlifke (Lygature), Thanos Stavropoulos and Ioulietta Lazarou (CERTH), Nikolay Manyakov (the Janssen Pharmaceutical Companies of Johnson and Johnson) and Emilio Merlo Pich (Takeda Pharmaceuticals) joined the meeting, and together with Dianne Gove and Ana Diaz (AE) co-moderated the discussions. The research team stated that they appreciated the input from the group, as it provided a unique patient perspective and found it very useful for the continuation of the project.

The PAB will contribute towards several discussions about relevant issues during the whole duration of the project. In addition to interested members from the EWGPWD and their supporters, people with Mild Cognitive Impairment, people at higher risk of developing Alzheimer’s dementia and members of national Alzheimer organisations will also have the opportunity to contribute to this work and join the PAB. 

Read more about the EWGPWD here